Massive study pits tirzepatide against rivals for heart protection
NCT ID NCT06779929
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This completed study looked at insurance claims data from 70,000 people with type 2 diabetes and established heart disease to compare the heart-related risks of three diabetes drugs: tirzepatide, dulaglutide, and semaglutide. The goal was to see if any of these drugs was linked to fewer heart attacks, strokes, or deaths. Because it used existing data rather than a controlled experiment, the findings can suggest but not prove which drug might be safer for the heart.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
tirzepatide, dulaglutide, semaglutide
What this could lead to
If this study shows one drug is better at preventing heart attacks or strokes, it could guide doctors to choose the most effective treatment for people with type 2 diabetes and heart disease.
What could go wrong
This is an observational study using insurance claims, not a randomized trial, so results may be influenced by unmeasured factors. It cannot prove cause and effect.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Brigham and Women's Hospital
Boston, Massachusetts, 02120, United States